Physicians

Department / Division
Medicine / Medicine - Cellular Therapy Division

Address
DUMC 3961
Durham, NC 27710

Appointment Telephone
919-668-1027

Office Telephone
919-668-1045

Fax Telephone
919-668-1091

Training

• MD, Wake Forest University School of Medicine (North Carolina), 1983

Residency

• Internal Medicine, Vanderbilt University Medical Center (Tennessee), 1983-1986
• Medical Oncology, Stanford University Medical Center (California), 1987-1990

Clinical Interests
Bone-marrow transplantation (allogeneic and autologous) for hematologic malignancies and solid tumors; multiple myeloma

Research Interests
1. High dose therapy and autologous and allogeneic stem cell rescue for hematologic malignancies (especially multiple myeloma) and solid tumors.  
2. Non-myeloablative allogeneic transplants for hematologic malignancies and solid tumors.
3. Supportive care for hematopoietic stem cell transplants.
4. Prevention and therapy of graft versus host disease.

Industry Relationships and Collaborations (What's this?)

This physician has no reported relationships with industry.

Representative Publications
5. Horning SJ, Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, Long GD, Brown BW and Blume KG. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial. Blood 97: 404-409, 2001. (2001)

4. Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ and Peters WP. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem cell support. J Clin Oncol 17: 3064-3074, 1999. (1999)

3. Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ and Blume KG. Fractionated total body irradiation, etoposide and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high risk or advanced stage hematological malignancies. Biol Blood Marrow Transplant 3: 324-330, 1997. (1997)

2. Long GD, Chao NJ, Hu WW, Negrin RS, Wong RM and Blume KG. High-dose etoposide based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma. Cancer 78: 2502-2509, 1996. (1996)

Long GD, Negrin RS, Hoyle CF, Kusnierz-Glas CR, Schriber JR, Blume KG and Chao NJ. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. Cancer 76: 860-868, 1995. (1995)